Started mass production of Electrospider, the 3D bioprinter that replicates human tissue

Born from the experimental project conducted in collaboration with the University of Pisa, the bioprinter will now be mass-produced

Bio3DPrinting, a SolidWorld GROUP company, has started the production of Electrospider, the 3D bioprinter capable of producing tissues using the same cells of the patient to which it will be implanted. After a long and meticulous experimental phase, the series production of Electrospider was started, whose production capacity in this first phase is 12 printers.

The Electrospider 3D bioprinter

Electrospider is the 3D bioprinter born from the synergistic collaboration between the world of research, university and industry, which sees our company Bio3DPrinting as protagonists, with a plant in Barberino Tavarnelle (FI) and belonging to the SolidWorld GROUP listed on the Euronect Growth segment of Borsa Italiana, and the Biofabrication group of the Research Center “E. Piaggio" of the University of Pisa, directed by Professor Giovanni Vozzi.

The only 3D bioprinter in the world capable of recreating biological tissues compatible with human beings thanks to the printing of innovative hydrogels loaded with the subject's cells, Electrospider can have different applications: in the biomedical field, the long-term goal is to reconstruct transplanted organs and tissues starting from the patient's own cells or even from blood relatives, significantly reducing hospitalization times. In particular, today the Electrospider is very useful in the oncology field, as it is able to create smaller tissue structures to test the effectiveness of the therapy and then apply them to the patient.

In the pharmacological and cosmetic fields, tissue replication makes it possible to test drugs, creams and products, making them safer for humans. Finally, it can also be used in the fashion sector, where it will be possible to create accessories and leather goods starting from animal biopsies.

Roberto Rizzo, founder and president of SolidWorld GROUP commented: “3D bioprinting, although a relatively new technology, constitutes an epochal evolution for the biofabrication of functional tissues at the service of Tissue and Regenerative Medicine, pharmacological and cosmetic research and testing processes and production of drugs and cosmetic products. Electrospider is the first multi-scale and multi-material 3D bioprinting technology capable of generating 3D cellular constructs having the complex topology of human tissues. It is a real revolution in the world of 3D printing for medical purposes that the SolidWorld group is able to put at the service of the most important healthcare facilities around the world”.

Related posts